YenePharma

Yantai YenePharma Co., Ltd. is a clinical-stage biotechnology company based in Yantai, China, focused on the development of innovative sublingual drug delivery systems for central nervous system and cardiovascular disorders. The company's lead product candidate, Y-2 (branded as Sanbexin sublingual), is a combination of edaravone and dexborneol designed to provide rapid brain cytoprotection by scavenging free radicals and inhibiting inflammatory responses. Sanbexin sublingual received NMPA approval in China in 2023 for the treatment of acute ischemic stroke, offering a non-invasive and potentially faster-acting alternative to traditional intravenous neuroprotective therapies. YenePharma maintains a strong strategic partnership with Simcere Pharmaceutical Group, which handles the commercialization and clinical expansion of its core assets. The company's research pipeline also explores the application of its sublingual technology in indications such as hemorrhagic stroke, Alzheimer's disease, and Sjögren's syndrome.